A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Recent evidence suggests that Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs) can assist in alcohol and related substance use disorders (ASUD). GLP-1RAs act on the same receptor targets as native GLP-1, but last from several hours to a week, com…
TOPIC: This systematic review and meta-analysis evaluates the rate and risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults receiving semaglutide for diabetes or weight loss. CLINICAL RELEVANCE: Semaglutide is a transformative tr…
OBJECTIVE: This study aimed to characterize the reasons for treatment discontinuation with injectable semaglutide or tirzepatide for obesity in regular clinical practice. METHODS: This cross-sectional study used electronic health record data between…
The purpose of this exploratoryanalysis was to study the impact of semaglutide on measures of bone health in older adults. Data were collected from a 20-week pilot trial (NCT05786521), which randomized 20 older adults (72.7 ± 4.8 years of age, 50% wo…
Semaglutide (Sema), a potent glucagon-like peptide-1 receptor agonist, is widely used in the management of type 2 diabetes mellitus due to its glucose-lowering effects. Beyond this, Sema also exhibits antioxidative, anti-inflammatory, antiapoptotic,…
AIMS: To compare major limb events in individuals with type 2 diabetes who initiated either injective or oral semaglutide versus other glucose-lowering therapies (GLT) in a real-world setting. MATERIALS AND METHODS: This was a single-centre retrospec…
AIM: This meta-analysis aims to evaluate the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RAs), on new-onset atrial fibrillation (AF) in randomized clinical trials (RCTs). METHODS AND RESULTS: Twenty-six RCTs involving 48,…
Ozempic (semaglutide) was first authorized to treat type 2 diabetes, but because of its appetite-suppressing properties, it has become popular off-label for weight loss. According to clinical investigations, GLP-1 significantly decreases blood sugar…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce bodyweight and blood glucose. Extensive evidence from randomized controlled trials has indicated that GLP-1RAs have benefits well beyond weight loss and glucose control, extending from reduc…
AIMS: To compare the effects of semaglutide and testosterone replacement therapy (TRT) on semen quality and parameters of functional hypogonadism (FH) in men with type 2 diabetes mellitus and obesity. MATERIALS AND METHODS: We designed a randomised o…
Obesity is a chronic disease with an increasing worldwide prevalence. Improving obesity is of paramount importance given its association with conditions such as type 2 diabetes, cardiovascular disease, and cancer among others. In the last decade, a n…
BACKGROUND: Type 2 diabetes (T2D), affecting approximately 12% of the global population and over 30% of older adults, is among the most prevalent and fast-growing risk factors for neurodegenerative disorders. Evidence is lacking on whether specific g…
Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of drugs, most well known by the third-generation once-weekly subcutaneous semaglutide, that act on the incretin pathway of metabolic, hormonal signaling to modulate pancreatic insulin re…
BACKGROUND: Social media has been extensively used by the public to seek information and share views on health issues. Recently, the proper and off-label use of semaglutide drugs for weight loss has attracted huge media attention and led to temporary…
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a well-established agent in managing patients with high cardiovascular risk. Initially, a formulation was introduced for weekly subcutaneous administration that demonstrated good tolerabilit…
BACKGROUND: The FLOW clinical trial recently demonstrated that the glucagon-like peptide-1 receptor agonist once-weekly semaglutide 1 mg was associated with kidney- and cardio-protective effects (the latter already shown in the SUSTAIN 6 trial) compa…
The present study aimed to explore how semaglutide can help protect the heart from injury caused by hypoxia/reoxygenation (H/R) and to reveal the underlying mechanism. Briefly, AC16 cardiomyocytes were subjected to 8 h of hypoxia followed by 12 h of…